The following is a summary of the Xeris Biopharma Holdings, Inc. (XERS) Q3 2024 Earnings Call Transcript:

Financial Performance:

• Xeris Biopharma reported Q3 2024 total revenue of $54.3 million, with product revenue of $52.9 million, marking a significant 27% growth year-over-year.

• Net product revenue for the year-to-date was $139.6 million, reflecting an increase of about 26% compared to the prior year.

• The company raised its full-year revenue guidance to $198 million to $202 million, reflecting strong performance and growing market share.

• The financial discipline and strategic investments have contributed to maintaining a robust cash position of over $69 million, affirming no need for dilutive financing.

Business Progress:

• Recorlev and Gvoke led the product portfolio with strong sales growth and significant market share gains.

• Recorlev sales reached approximately $18 million, growing by 119% over Q3 2023 and 33% over the last quarter.

• XP8121, a pipeline product for hypothyroidism, has shown positive Phase 2 clinical data and is advancing towards Phase 3 with the FDA.

• The company has executed planned expansions and investments in technology partnerships, enhancing research and development capabilities.

Opportunities:

• Xeris is experiencing strong market tailwinds for Recorlev due to an expanding Cushing syndrome market where more people are being diagnosed and treated.

• The total addressable patient population for Gvoke, targeting severe hypoglycemia in diabetes, remains largely untapped, providing significant growth potential with extended patent protection until 2036.

Risks:

• Competitive pressures and potential entry of generic products could affect the market position of Keveyis, although current defenses and patient loyalty have so far maintained its brand strength.

More details: Xeris Pharmaceuticals IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.